BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive skin cancer with a recurrence rate of >40%. Of the 2000 MCC cases per year in the United States, most are caused by the Merkel cell polyomavirus (MCPyV). Antibodies to MCPyV oncoprotein (T-antigens) have been correlated with MCC tumor burden. The present study assesses the clinical utility of MCPyV-oncoprotein antibody titers for MCC prognostication and surveillance. METHODS: MCPyV-oncoprotein antibody detection was optimized in a clinical laboratory. A cohort of 219 patients with newly diagnosed MCC were followed prospectively (median follow-up, 1.9 years). Among the seropositive patients, antibody titer and disease status were serially tracked. RESULTS: Antibodies to MCPyV oncoproteins were rare among healthy individuals (1%) but were present in most patients with MCC (114 of 219 patients [52%]; P < .01). Seropositivity at diagnosis independently predicted decreased recurrence risk (hazard ratio, 0.58; P = .04) in multivariate analyses adjusted for age, sex, stage, and immunosuppression. After initial treatment, seropositive patients whose disease did not recur had rapidly falling titers that became negative by a median of 8.4 months. Among seropositive patients who underwent serial evaluation (71 patients; 282 time points), an increasing oncoprotein titer had a positive predictive value of 66% for clinically evident recurrence, whereas a decreasing titer had a negative predictive value of 97%. CONCLUSIONS: Determination of oncoprotein antibody titer assists in the clinical management of patients with newly diagnosed MCC by stratifying them into a higher risk seronegative cohort, in which radiologic imaging may play a more prominent role, and into a lower risk seropositive cohort, in which disease status can be tracked in part by oncoprotein antibody titer. Cancer 2017;123:1464-1474.
BACKGROUND:Merkel cell carcinoma (MCC) is an aggressive skin cancer with a recurrence rate of >40%. Of the 2000 MCC cases per year in the United States, most are caused by the Merkel cell polyomavirus (MCPyV). Antibodies to MCPyV oncoprotein (T-antigens) have been correlated with MCCtumor burden. The present study assesses the clinical utility of MCPyV-oncoprotein antibody titers for MCC prognostication and surveillance. METHODS:MCPyV-oncoprotein antibody detection was optimized in a clinical laboratory. A cohort of 219 patients with newly diagnosed MCC were followed prospectively (median follow-up, 1.9 years). Among the seropositive patients, antibody titer and disease status were serially tracked. RESULTS: Antibodies to MCPyV oncoproteins were rare among healthy individuals (1%) but were present in most patients with MCC (114 of 219 patients [52%]; P < .01). Seropositivity at diagnosis independently predicted decreased recurrence risk (hazard ratio, 0.58; P = .04) in multivariate analyses adjusted for age, sex, stage, and immunosuppression. After initial treatment, seropositive patients whose disease did not recur had rapidly falling titers that became negative by a median of 8.4 months. Among seropositive patients who underwent serial evaluation (71 patients; 282 time points), an increasing oncoprotein titer had a positive predictive value of 66% for clinically evident recurrence, whereas a decreasing titer had a negative predictive value of 97%. CONCLUSIONS: Determination of oncoprotein antibody titer assists in the clinical management of patients with newly diagnosed MCC by stratifying them into a higher risk seronegative cohort, in which radiologic imaging may play a more prominent role, and into a lower risk seropositive cohort, in which disease status can be tracked in part by oncoprotein antibody titer. Cancer 2017;123:1464-1474.
Authors: Tingting Chen; Lea Hedman; Petri S Mattila; Tuomas Jartti; Olli Ruuskanen; Maria Söderlund-Venermo; Klaus Hedman Journal: J Clin Virol Date: 2010-11-19 Impact factor: 3.168
Authors: Masahiro Shuda; Reety Arora; Hyun Jin Kwun; Huichen Feng; Ronit Sarid; María-Teresa Fernández-Figueras; Yanis Tolstov; Ole Gjoerup; Mahesh M Mansukhani; Steven H Swerdlow; Preet M Chaudhary; John M Kirkwood; Michael A Nalesnik; Jeffrey A Kant; Lawrence M Weiss; Patrick S Moore; Yuan Chang Journal: Int J Cancer Date: 2009-09-15 Impact factor: 7.396
Authors: Roland Houben; Masahiro Shuda; Rita Weinkam; David Schrama; Huichen Feng; Yuan Chang; Patrick S Moore; Jürgen C Becker Journal: J Virol Date: 2010-05-05 Impact factor: 5.103
Authors: Michelle Heath; Natalia Jaimes; Bianca Lemos; Arash Mostaghimi; Linda C Wang; Pablo F Peñas; Paul Nghiem Journal: J Am Acad Dermatol Date: 2008-03 Impact factor: 11.527
Authors: Diana V Pastrana; Yanis L Tolstov; Jürgen C Becker; Patrick S Moore; Yuan Chang; Christopher B Buck Journal: PLoS Pathog Date: 2009-09-11 Impact factor: 6.823
Authors: Paul T Nghiem; Shailender Bhatia; Evan J Lipson; Ragini R Kudchadkar; Natalie J Miller; Lakshmanan Annamalai; Sneha Berry; Elliot K Chartash; Adil Daud; Steven P Fling; Philip A Friedlander; Harriet M Kluger; Holbrook E Kohrt; Lisa Lundgren; Kim Margolin; Alan Mitchell; Thomas Olencki; Drew M Pardoll; Sunil A Reddy; Erica M Shantha; William H Sharfman; Elad Sharon; Lynn R Shemanski; Michi M Shinohara; Joel C Sunshine; Janis M Taube; John A Thompson; Steven M Townson; Jennifer H Yearley; Suzanne L Topalian; Martin A Cheever Journal: N Engl J Med Date: 2016-04-19 Impact factor: 91.245
Authors: M Samimi; L Molet; M Fleury; H Laude; A Carlotti; C Gardair; M Baudin; L Gouguet; E Maubec; M Avenel-Audran; E Esteve; E Wierzbicka-Hainaut; N Beneton; F Aubin; F Rozenberg; N Dupin; M F Avril; G Lorette; S Guyetant; P Coursaget; A Touzé Journal: Br J Dermatol Date: 2016-02-03 Impact factor: 9.302
Authors: Linde M van Veenendaal; Eduardo Bertolli; Catharina M Korse; W Martin C Klop; Margot E T Tesselaar; Alexander C J van Akkooi Journal: Ann Surg Oncol Date: 2020-06-11 Impact factor: 5.344
Authors: Kaiji Fan; Cathrin Ritter; Paul Nghiem; Astrid Blom; Monique E Verhaegen; Andrzej Dlugosz; Niels Ødum; Anders Woetmann; Richard W Tothill; Rodney J Hicks; Michael Sand; David Schrama; Dirk Schadendorf; Selma Ugurel; Jürgen C Becker Journal: Clin Cancer Res Date: 2018-07-30 Impact factor: 12.531
Authors: Dirk Schadendorf; Paul Nghiem; Shailender Bhatia; Axel Hauschild; Philippe Saiag; Lisa Mahnke; Subramanian Hariharan; Howard L Kaufman Journal: Oncoimmunology Date: 2017-08-31 Impact factor: 8.110
Authors: Anish A Butala; Varsha Jain; Vishruth K Reddy; Ronnie A Sebro; Yun Song; Giorgos Karakousis; Tara C Mitchell; J Nicholas Lukens; Jacob E Shabason Journal: Oncologist Date: 2020-09-17
Authors: Jürgen C Becker; Andreas Stang; Axel Zur Hausen; Nicole Fischer; James A DeCaprio; Richard W Tothill; Rikke Lyngaa; Ulla Kring Hansen; Cathrin Ritter; Paul Nghiem; Christopher K Bichakjian; Selma Ugurel; David Schrama Journal: Cancer Immunol Immunother Date: 2017-11-30 Impact factor: 6.968
Authors: Morgan Guénolé; Paolo Bénigni; Vincent Bourbonne; François Lucia; Delphine Legoupil; Olivier Pradier; Laurent Misery; Arnaud Uguen; Ulrike Schick Journal: J Cancer Res Clin Oncol Date: 2021-06-11 Impact factor: 4.553